Information Provided By:
Fly News Breaks for February 16, 2018
PCRX, HRTX
Feb 16, 2018 | 08:56 EDT
Heron Therapeutics' (HRTX) HTX-011 gained an edge yesterday after an FDA advisory committee recommended not to approve Pacira Pharmaceuticals' (PCRX) proposed label expansion for Exparel, Lake Street analyst Bruce Jackson tells investors in a research note. Heron believes it has addressed the issues raised by the FDA panel with its Phase 3 study, the results for which are expected between late Q1/mid Q2, Jackson adds. The analyst keeps a Buy rating on Heron with a $42 price target.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX